Publicaciones

Beigene Medical Europa

Investigation of PD‑L1 expression and tislelizumab efficacy in gastroesophageal adenocarcinoma using a novel tumor and immune cell score with ventana PD-L1 (SP263) assay and combined positive score (CPS)

 Volver Ver
Investigation of PD‑L1 expression and tislelizumab efficacy in gastroesophageal adenocarcinoma using a novel tumor and immune cell score with ventana PD-L1 (SP263) assay and combined positive score (CPS)
 POSTER   09/2020
 Download  Ver

Para obtener más información sobre esta publicación, por favor envíe una solicitud de información médica.

Publicaciones relacionadas

PD1 inhibitors on the horizon for NSCLC: Current knowledge, future possibilities
PD1 inhibitors on the horizon for NSCLC: Current knowledge, future possibilities
BeiGene Presents Data at ESMO Virtual Congress 2020 on Phase 3 Trial of Tislelizumab in First-Line Non-Squamous Non-Small Cell Lung Cancer and Phase 2 Trial of Pamiparib in Advanced Ovarian Cancer
BeiGene Presents Data at ESMO Virtual Congress 2020 on Phase 3 Trial of Tislelizumab in First-Line Non-Squamous Non-Small Cell Lung Cancer and Phase 2 Trial of Pamiparib in Advanced Ovarian Cancer
Safety and efficacy of long-term exposure (LTE) to tislelizumab in chinese patients with advanced solid tumors
Safety and efficacy of long-term exposure (LTE) to tislelizumab in chinese patients with advanced solid tumors
 Volver
¿Necesita más información?
Service